SCHEMBL4495324

SCHEMBL4495324

CC(O)NC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.50
SLC6A4 P31645 1/20 0.42
CYP2D6 P10635 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALOX15 P16050 2/20 0.38
CYP3A4 P08684 2/20 0.38
ADRA2C P18825 2/20 0.38
KIF11 P52732 1/20 0.38
CHRM2 P08172 1/20 0.38
ADRA1A P35348 1/20 0.38
RGS12 O14924 1/20 0.38
GLA P06280 1/20 0.38
CYP2C9 P11712 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
ALOX12 P18054 1/20 0.38
NFKB1 P19838 1/20 0.38
HTR2A P28223 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19381442 0.83 KCNN4 (0.46) KCNN4SLC6A4CYP2D6CYP1A2CYP2C19
SCHEMBL27365381 0.81 KCNN4 (0.54) KCNN4SLC6A4CYP2D6CYP1A2CYP2C19
SCHEMBL9025613 0.77 KCNN4 (0.50) KCNN4SLC6A4CYP2D6CYP1A2CYP2C19
SCHEMBL16673174 0.77 KCNN4 (0.50) KCNN4SLC6A4CYP2D6CYP1A2CYP2C19
SCHEMBL2160833 0.77 KCNN4 (0.50) KCNN4SLC6A4CYP2D6CYP1A2ADRA2C
SCHEMBL10675289 0.77 KCNN4 (0.50) KCNN4SLC6A4CYP2D6CYP1A2CYP2C19
SCHEMBL9037241 0.77 KCNN4 (0.45) KCNN4CYP2D6CYP1A2CYP2C19KIF11
SCHEMBL11128706 0.77 KCNN4 (0.45) KCNN4CYP2D6CYP1A2CYP2C19KIF11
SCHEMBL2552806 0.77 KCNN4 (0.45) KCNN4SLC6A4CYP2D6CYP1A2CYP2C19
SCHEMBL16550481 0.77 KCNN4 (0.50) KCNN4SLC6A4CYP2D6CYP2C19HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-63054384-A None JP disclosed
US-20250215028-A1 SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS UNIVERSITE DE ROUEN-NORMANDIE (FR) 2025-07-03 US disclosed
US-9115122-B2 Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) UNIVERSITY OF MARYLAND, BALTIMORE (US) 2015-08-25 US disclosed
EP-2845587-A2 Melanin production inhibitor Pola Chemical Industries Inc. (JP) 2015-03-11 EP disclosed
US-20140179743-A1 NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) UNIVERSITY OF MARYLAND, BALTIMORE (US) 2014-06-26 US disclosed
US-7517858-B1 Prodrugs of pharmaceuticals with improved bioavailability THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-04-14 US disclosed
EP-0837630-B1 PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY HOSTETLER KARL Y (US) 2007-12-26 EP disclosed
EP-1196383-B1 PROCESS FOR PREPARING AMLODIPINE BENZENESULPHONATE RICHTER GEDEON VEGYESZET (HU) 2004-12-01 EP disclosed
WO-2003101965-A1 TWO CRYSTALLINE HYDRATE FORMS OF AMLODIPINE BENZENESULFONATE OF HIGH PURITY, PROCESSES FOR THEIR PREPARATION AND USE LEK PHARMACEUTICALS D.D. (SI) 2003-12-11 WO disclosed
US-6596874-B1 Salt formation by reaction using benzenesulfonic acid RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2003-07-22 US disclosed
US-5245038-A Fluorescent poly(arylpyridine) rare earth chelates BAXTER DIAGNOSTICS INC. (US) 1993-09-14 US disclosed
EP-0556216-A1 PHOSPHORIC ACID ESTERS AND THEIR USE IN THE PREPARATION OF BIOCOMPATIBLE SURFACES. BIOCOMPATIBLES LTD (GB) 1993-08-25 EP disclosed
US-5116989-A Fluorescent poly(arylpyridine) rare earth chelates BAXTER DIAGNOSTICS INC. (US) 1992-05-26 US disclosed
WO-1992007858-A1 PHOSPHORIC ACID ESTERS AND THEIR USE IN THE PREPARATION OF BIOCOMPATIBLE SURFACES BIOCOMPATIBLES LIMITED (GB) 1992-05-14 WO disclosed
US-5106957-A Fluorescent poly(arylpyridine) rare earth chelates BAXTER DIAGNOSTICS INC. (US) 1992-04-21 US disclosed
US-5055578-A Fluorescent poly(arylpyridine) rare earth chelates BAXTER DIAGNOSTICS INC. (US) 1991-10-08 US disclosed
US-5032677-A Fluorescent poly(arylpyridine) rare earth chelates BAXTER INTERNATIONAL INC. (US) 1991-07-16 US disclosed
EP-0383281-A1 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same TOYAMA CHEMICAL CO., LTD. (JP) 1990-08-22 EP disclosed
EP-0341298-A1 FLUORESCENT POLY(ARYLPYRIDINE) RARE EARTH CHELATES Baxter Diagnostics Inc. (US) 1989-11-15 EP disclosed
JP-S6354384-A MIXED ACID-TYPE POLYMERIZABLE PHOSPHOLIPID DERIVATIVE AND PRODUCTION THEREOF TOSOH CORP 1988-03-08 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215028-A1 SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS PHOSPHO1, SGMS1, SGPL1 KCNN4 3964/4885SLC6A4 4576/4885CYP2D6 1978/4885
US-20140179743-A1 NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) MAPK1, MAP3K1, MAP3K20 KCNN4 4035/4885SLC6A4 4396/4885CYP2D6 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.